ProMIS Neurosciences Doses First Patients in Phase 1b PRECISE-AD Trial of PMN310 for Alzheimer's Disease
Portfolio Pulse from
ProMIS Neurosciences has dosed the first patients in its Phase 1b trial of PMN310 for Alzheimer's, highlighting the urgent need for better treatments. Interim results are expected in the first half of 2026, with topline results in the second half.
February 25, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProMIS Neurosciences has initiated dosing in its Phase 1b trial for PMN310, targeting Alzheimer's disease. This milestone could impact the company's stock as it progresses towards interim results in 2026.
The initiation of patient dosing in a clinical trial is a significant milestone for a biotech company, often leading to increased investor interest and potential stock price movement. The anticipation of interim results in 2026 adds to the potential positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100